Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Prezista

PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 15–16

HOS-116363 · Präparat HOS-094447

15 ANTIBIOTIC Clarithromycin clarithromycin AUC ↑ 57% Caution should be exercised when 500 mg twice daily clarithromycin Cmin ↑ 174% clarithromycin is combined with clarithromycin Cmax ↑ 26% boosted PREZISTA. # darunavir AUC ↓ 13% # darunavir Cmin ↑ 1% For patients with renal impairment # the Summary of Product darunavir Cmax ↓ 17% Characteristics for clarithromycin 14-OH-clarithromycin concentrations should be consulted for the were not detectable when combined with recommended dose. PREZISTA/ritonavir. (↑ clarithromycin from CYP3A inhibition and possible P-gp inhibition) ANTICOAGULANT/PLATELET AGGREGATION INHIBITOR Apixaban Not studied. Co-administration of The use of boosted PREZISTA Rivaroxaban boosted PREZISTA with these with a direct oral anticoagulant anticoagulants may increase (DOAC) that is metabolised by concentrations of the anticoagulant. CYP3A4 and transported by P-gp (CYP3A and/or P-gp inhibition) is not recommended as this may lead to an increased bleeding risk. Dabigatran etexilate dabigatran etexilate (150 mg): Darunavir/ritonavir: Edoxaban darunavir/ritonavir 800/100 mg single Clinical monitoring and/or dose dose: reduction of the DOAC should be dabigatran AUC ↑ 72% considered when a DOAC dabigatran Cmax ↑ 64% transported by P-gp but not metabolised by CYP3A4, darunavir/ritonavir 800/100 mg once including dabigatran etexilate and daily: edoxaban, is co-administered with dabigatran AUC ↑ 18% PREZISTA/rtv. dabigatran Cmax ↑ 22% Darunavir/cobicistat: darunavir/cobicistat 800/150 mg single Clinical monitoring and dose dose: reduction is required when a dabigatran AUC ↑ 164% DOAC transported by P-gp but not dabigatran Cmax ↑ 164% metabolised by CYP3A4, including dabigatran etexilate and darunavir/cobicistat 800/150 mg once edoxaban, is co-administered with daily: PREZISTA/cobi. dabigatran AUC ↑ 88% dabigatran Cmax ↑ 99% Ticagrelor Concomitant administration of Based on theoretical considerations, boosted PREZISTA with ticagrelor co-administration of boosted PREZISTA is contraindicated (see section 4.3). with ticagrelor may increase concentrations of ticagrelor (CYP3A and/or P-glycoprotein inhibition). Clopidogrel Co-administration of clopidogrel Not studied. Co-administration of with boosted PREZISTA is not clopidogrel with boosted PREZISTA is recommended. Use of other expected to decrease clopidogrel active antiplatelets not affected by CYP metabolite plasma concentration, which inhibition or induction (e.g. may reduce the antiplatelet activity of prasugrel) is recommended. clopidogrel. Warfarin Not studied. Warfarin concentrations may It is recommended that the be affected when co-administered with international normalised ratio boosted PREZISTA. (INR) be monitored when warfarin is combined with boosted PREZISTA.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) cobicistat (HOS-088111) dabigatran (HOS-112096) rivaroxaban (HOS-086236) lead (HOS-085592) clopidogrel (HOS-087927) clarithromycin (HOS-084517) edoxaban (HOS-086234) apixaban (HOS-112091) prasugrel (HOS-112066) ritonavir (HOS-084521) dabigatran etexilate (HOS-086233) warfarin (HOS-085950)